Conference abstract · 12 Mar 2018
Conference abstractPublished 29 Mar 2018
Bridging the MOA and the POC for clinical application: A case study
National Institute of Biomedical Innovation, Health and Nutrition, Japan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Once the manufactured cells were assigned for cell-based medicinal products, non-clinical studies shall be conducted. In the constructed non-clinical study package including in vitro and/or in vivo studies: (1) the mode of action (MOA) should be shown, (2) the proof of concept (POC) to be acquired and (3) safety of the candidates be examined. In this presentation, we will focus on MOA and POC and bridge these two concepts, in which adipose tissue-derived multi-lineage progenitor cells (ADMPCs) would be developed as cell-based medicinal products for liver fibrosis. To treat the patients with the liver cirrhosis, the pathogenesis and pathophysiology should be concerned to the MOA. Liver fibrosis is characterized by excessive accumulation of extracellular matrix with inflammatory status in situ, therefore, in the developing cell-based medicinal products, anti-inflammatory cytokines and fibrinolytic enzyme secretion is anticipated as MOA. After showing the appropriate MOA, the MOA and the POC should be bridges and the key issues are what kind of animal models should be selected. In the case of the developing cell-based products, MOA is that the cells act as vehicle for the delivery of anti-inflammatory cytokines and MMPs. Tetra carbon chloride (CCl4)chronic induction evolved radicals, followed by inflammation, resulted in fibrosis of the parenchyma. So, the expected mode could be applicable in this animal model. To acquire the POC after bridging to MOA, the appropriate route of administration (ROA) should be concerned. In the case study, the POC of the developing cell-based products by the improvement of liver fibrosis, function by systemic administration of ADMPC. In conclusion it can be said that: (1) MOA should be planned from the pathophysiology of the target diseases, (2) the POC-study should be designed to bridge to the MOA and (3) the applicable limitation should be concerned in clinical use for the patients of the disease. Recent Publications 1. Okura H, Morita M, Fujita M, Naba K, Takada N, Takagaki Y, Suzuki O, Matsuyama A (2017) Therapeutic potential of adipose tissue-derived multi-lineage progenitor cell-sheets on liver fibrosis. Journal of Translational Science; 4: 1-6. 2. Negoro T, Okura H, Matsuyama A (2017) Induced Pluripotent Stem Cells: Global Research Trends. Biores Open Access; 6: 63-73.
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Perspective · 19 Oct 2023
Bridging the gap from basic research to clinical practice in toxicology studies
Commentary · 28 Jun 2023
Toxicity biomarkers: Bridging the gap between clinical observations & experimental evidence.
Perspective · 21 Dec 2025
Translational Genomics: Bridging Basic Research and Clinical Applications
Article · 28 Mar 2025
Clinical Trials in Pharmacology: Bridging Research and Therapeutic Application
More from this journal
The newest in Toxicology: Open Access.
Editorial · 1 Dec 2025
Aflatoxin Contamination: Health Risks and Solutions
Editorial · 1 Dec 2025
Heavy Metals: Toxicity, Risks, and Prevention
Editorial · 1 Dec 2025
Occupational Health and Safety: Key Research Areas
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalToxicology: Open Access
- SubjectToxicology
- BylineArticles whose byline prints “Hanayuki Okura”
- BylineArticles whose byline prints “Akifumi Matsuyama”
